Belite Bio, Inc - Depositary Receipt (BLTE) Price Target Increased by 11.24% to 215.73

Average one-year price target for Belite Bio (NasdaqCM:BLTE) was raised to $215.73/share, an 11.24% increase from the prior $193.93 target dated Feb 21, 2026. The update reflects a revised consensus average of multiple analyst targets and signals modestly improved analyst outlook for the company.

Analysis

Average one-year price target for Belite Bio (NasdaqCM:BLTE) was raised to $215.73/share, an 11.24% increase from the prior $193.93 target dated Feb 21, 2026. The update reflects a revised consensus average of multiple analyst targets and signals modestly improved analyst outlook for the company.